Local intraluminal infusion of biodegradable polymeric nanoparticles: A novel approach for prolonged drug delivery after balloon angioplasty

Circulation

Volumn 94, Issue 6, 1996, Pages 1441-1448

  Guzman, Luis A ^a   Labhasetwar, Vinod ^b   Song, Cunxian ^b   Jang, Yangsoo ^a   Lincoff, A Michael ^a   Levy, Robert ^b   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

angioplasty; arteries; balloons; drugs; nanoparticles

Indexed keywords

DEXAMETHASONE; NANOPARTICLE; POLYGLACTIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG INFUSION; DRUG PENETRATION; DRUG RETENTION; HISTOCOMPATIBILITY; INTRAARTERIAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHARMACOKINETICS; PHARMACOLOGY; PRIORITY JOURNAL; RAT;

EID: 0029815022     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.6.1441     Document Type: Article

References (49)

1. Hillegass WB, Ohman EM, Califf RM. Restenosis: the clinical issue. In: Topol EJ, ed. Textbook of Interventional Cardiology. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1994:415-435.
2. Popma JJ, Califf RM, Topol EJ. Clinical trials of restenosis following coronary angioplasty. Circulation. 1991;84:1426-1436.
3. Weintraub WS, Boccuzzi SJ, Klein JL, Kosinski AS, King SB, Ivanhoe R, Cedarholm JC, Stillabower ME, Talley JD, DeMaio SJ, O'Neill WW, Frazier JE, Cohen-Bernstein CL, Robbins DC, Brown CL, Alexander RW. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med. 1994;331:1331-1337.
4. Serruys PW, Rutsch W, Heyndrickx GR, Danchin N, Mast EG, Wijns W, Rensing BJ, Vos J, Stibbe J, for the Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study Group (CARPORT). Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade: a randomized, double-blind, placebo-controlled trial. Circulation. 1991;84:1568-1580.
5. The Multicenter European Research Trial with Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin-converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR Study. Circulation. 1992;86:100-110.
6. Kent KM, Williams DO, Cassagneau B, Broderick T, Chapekis A, Simpfendorfer C, Cote G, Bates E, Tauscher G, Kuntz RE, Popma JJ, Foegh M. Double blind, controlled trial of the effect of angiopeptin on coronary restenosis following balloon angioplasty. Circulation. 1993;88(suppl I):I-506. Abstract.
7. Thornton MA, Gruentzig AR, Hollman J, King SB III, Douglas JS. Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study. Circulation. 1984;69: 721-727.
8. Whitworth HB, Roubin GS, Hollman J, Meier B, Leimgruber PP, Douglas JS Jr, King SB III, Gruentzig AR. Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1986;8:1271-1276.
9. O'Keefe JHJ, McCallister BD, Bateman TM, Kuhnlein DL, Ligon RW, Hartzler GO. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol. 1992;19:1597-1600.
10. Villa A, Guzman L, Chen W, Golomb G, Levy R, Topol E. Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J Clin Invest. 1994;93:1243-1249.
11. Okada T, Bark DH, Mayberg MR. Localized release of perivascular heparin inhibits intimal proliferation after endothelial injury without systemic anticoagulation. Neurosurgery. 1989;25:892-898.
12. Edelman ER, Adams DH, Karnovsky MJ. Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc Natl Acad Sci U S A. 1990;87: 3773-3777.
13. Wolinsky H, Thung SN. Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J Am Coll Cardiol. 1990;15:475-481.
14. Lambert C, Leone J, Rowland S. Local drug delivery catheters: functional comparison of porous and microporous designs. Coron Artery Dis. 1993;4:469-475.
15. Hong M, Wong S, Farb A, Mehlman M, Virmani R, Barry J, Leon M. Feasibility and drug delivery efficiency of a new balloon angioplasty catheter capable of performing simultaneous local drug delivery. Coron Artery Dis. 1993;4:1023-1027.
16. Lincoff AM, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis: fact, fancy, and future. Circulation. 1994;90:2070-2084.
17. Fernandez-Ortiz A, Meyer BJ, Mailhac A, Falk E, Badimon L, Fallon JT, Fuster V, Chesebro JH, Badimon JJ. A new approach for local intravascular drug delivery: iontophoretic balloon. Circulation. 1994;89:1518-1522.
18. Mitchel J, Azrin M, Fram D, Schwedick M, Alberghini T, Waters D, McKay M. Intramural deposition of urokinase at the angioplasty site: comparative efficiency of systemic and local drug delivery techniques. Circulation. 1994;90(suppl I):I-20. Abstract.
19. Lincoff A, Furst J, Penn M, Lee P, MacIsaac A, Chisolm G, Topol E. Efficiency of solute transfer by a microporous balloon catheter in the porcine coronary model of arterial injury. J Am Coll Cardiol. 1994;28:18A. Abstract.
20. 3 catheter. J Am Coll Cardiol. 1994;23:186A. Abstract.
21. Kelly R. Clinical and laboratory evaluation of a new synthetic absorbable suture. Rev Surg. 1970;2:142-143.
22. Schindler A, Jeffcoat R, Kimmel G, Pitt C, Wall M, Zweidinger R. Biodegradable polymers for sustained drug delivery. Contemp Top Polym Sci. 1977;2:251-287.
23. Simons M, Edelman E, DeKeyser J-L, Langer R, Rosenberg R. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature. 1992;359:67-70.
24. Muller DWM, Ellis SG. Advances in coronary angioplasty: endovascular stents. Coron Artery Dis. 1990;1:438-448.
25. Zidar J, Lincoff A, Stack R. Biodegradable stents. In: Topol EJ, ed. Textbook of Interventional Cardiology. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1994:787-802.
26. Dev V, Zeng H, Forrester J, Eigler N, Hickey A, Fishbein M, Kupfer J, Litvack F. Microspheres for drug delivery in the arterial wall: a study of kinetic, toxicity, and effect of corticosteroid loaded microspheres. J Am Coll Cardiol. 1994;88:I-310. Abstract.
27. Aguado M, Lambert P. Controlled-release vaccine-biodegradable polylactide/polyglycolide(PL/PG) microspheres as antigen vehicles. Immunobiol. 1992;184:113-125.
28. Beck L, Pope V, Flowers C, Cowsar D, Tice T, Lewis D, Dunn R, Moore A, Gilley R. Poly(DL-lactide-co-glycolide)/norethisterone microcapsule: an injectable biodegradable contraceptive. Biol Reprod. 1983;28:186-195.
29. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science. 1994;263:1600-1603.
30. Villa A, Guzman L, Poptic E, Labhasetwar V, D'Souza S, Farrell C, Plow E, Levy R, DiCorleto P, Topol E. The effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vascular injury. Circ Res. 1995;76:505-513.
31. Rome JJ, Shayani V, Flugelman MY, Newman KD, Farb A, Virmani RK, Dichek DA. Anatomic barriers influence the distribution of in vivo gene transfer into the arterial wall: modeling with microscopic tracer particles and verification with a recombinant adenoviral vector. Arterioscler Thromb. 1994;14:148-161.
32. 131I-albumin within the media of the rabbit thoracic aorta. Circ Res. 1985;57:856-863.
33. Berk B, Raines E. Vascular smooth muscle growth inhibition by hydrocortisone is associated with decreased PDGF A chain expression. FASEB J. 1989;3(suppl A):A611. Abstract.
34. Berk B, Rao GN. Angiotensin II induced vascular smooth muscle cell hypertrophy: PDGF-A chain mediates increase in cell size. J Cell Physiol. 1993;154:368-380.
35. Ross R. The pathogenesis of atherosclerosis. N Engl J Med. 1986;314:488-499.
36. Ferns G, Raines E, Sprugel K, Motani A, Reidy M, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 1991;253:1129-1132.
37. Lee S, Tsou A, Chan H, Thomas J, Petrie K, Eugui E, Allison A. Glucocorticoids selectively inhibit the transcription of interleukin 1b gene and decrease the stability of interleukin 1b mRNA. Proc Natl Acad Sci U S A. 1988;85:1204-1208.
38. Libby P, Warner S, Friedman G. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest. 1988;81:487-498.
39. Raines E, Dower S, Ross R. Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science. 1989;243:393-396.
40. Schule R, Rangarajan P, Kliewer S, Ransone L, Bolado J, Yang N, Verna I, Evans R. Functional antagonism between oncoprotein c-jun and the glucocorticoid receptor. Cell. 1990;62:1217-1226.
41. Curran T, Franza B. Fos and jun: the AP-1 connection. Cell. 1988;55:395-397.
42. Cronstein B, Kimmel S, Levin R, Martiniuk F. A mechanism for the anti-inflammatory effect of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule L Proc Natl Acad Sci U S A. 1991;89:9991-9995.
43. Kling D, Fingerle J, Harlan J. Inhibition of leukocyte extravasation with a monoclonal antibody to CD18 during formation of experimental intimal thickening in rabbit carotid arteries. Arterioscler Thromb. 1992;12:997-1007.
44. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol. 1991;17:758-769.
45. Krane S, Amento E. Glucocorticoids and collagen disease. Adv Exp Med Biol. 1984;171:61-71.
46. Shapiro S, Campbell E, Kobayashi D, Welgus H. Dexamethasone selectively modulates basal and lypopolysaccharide-induced metalloproteinase and tissue inhibitor of metalloproteinase production by human alveolar macrophages. J Immunol. 1991;146:2724-2729.
47. Clark S, Kobayashi D, Welgus H. Regulation of the expression of tissue inhibitors of metalloproteinases and collagenases by retinoids and glucocorticoids in human fibroblasts. J Clin Invest. 1987; 80:1280-1288.
48. Kakuta T, Currier JW, Haudenschild CC, Ryan TJ, Faxon DP. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation. 1994;89:2809-2815.
49. Lafont A, Guzman L, Whitlow P, Goormastic M, Comhill J, Chisolm G. Restenosis after experimental angioplasty: intimal, medial, and adventitial changes associated with constrictive remodeling. Circ Res. 1995;76:996-1002.